Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. C-reactive protein after coronary artery bypass graft surgery and its relationship with postoperative atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Defibrillators for prevention from sudden cardiac death: is it that easy?-Authors' reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hypertension, cardiovascular disease and cause of death in Danish living kidney donors: matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Aims: After non-vitamin K antagonist (VKA) oral anticoagulation agents (NOAC) have been approved for thrombo-embolic prophylaxis in non-valvular atrial fibrillation (NVAF), utilization of oral anticoagulants (OAC) in NVAF has changed. Contemporary shifting from a VKA to a NOAC (dabigatran, rivaroxaban, or apixaban) has not been quantified, and could help assess whether these drugs are used according to recommendations.

Methods and results: Using Danish nationwide registries, we identified all VKA-experienced NVAF patients initiating a NOAC from 22 August 2011 to 31 December 2015 (shifters) and all VKA-experienced NVAF patients who were not switched to NOACs (non-shifters). Baseline characteristics and temporal utilization trends were examined. We included 62 065 patients with NVAF; of these, 19 386 (29.6%) shifted from a VKA to a NOAC (9973 (54.2%) shifted to dabigatran, 4775 (26.0%) to rivaroxaban, and 3638 (19.8%) to apixaban). Shifting was associated with lower age [odds ratio (OR) 0.95, 95% confidence interval (95% CI) 0.94-0.96 per 5 year increments], female gender (OR 1.33, 95% CI 1.28-1.38), and certain co-morbidities: more often stroke, bleeding, heart failure, and alcohol abuse, and less often hypertension, ischaemic heart disease, and diabetes. Shifting was common and initially dominated by shifting from VKA to dabigatran, but at the end of 2015, most shifters were shifted to rivaroxaban (45%) or apixaban (45%) whereas shifting to dabigatran decreased (to 10%).

Conclusion: In a contemporary setting among VKA-experienced NVAF patients; VKA is still prevalent although about 30% by December 2015 had shifted to a NOAC.

Original languageEnglish
JournalEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Volume20
Issue number6
Pages (from-to)e78-e86
ISSN1099-5129
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52050840